TAZ gene therapy reverses Barth syndrome in mice
Researchers have successfully treated cardiac dysfuntion in mice models of Barth syndrome by using a gene therapy to replace TAZ.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers have successfully treated cardiac dysfuntion in mice models of Barth syndrome by using a gene therapy to replace TAZ.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
Scientists have identified two master controller regions that are essential for alpha-synuclein aggregation and could be targeted by future therapies.
Scientists have identified that the TEX264 protein and associated enzymes protect the genome from damage, which could lead to new anti-ageing and neurodegeneration therapies.
An enzyme that adds a cell-signalling code to proteins has been identified by researchers, who say their discovery could aid in the development of cancer therapies.
A new population of stem cells that can generate bone has been revealed by researchers, which they say could have implications in regenerative medicine.
A collaborative team has developed a compound called WM382, which targets two crucial enzymes in the malaria parasite, effectively killing it.
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
Researchers have used cryogenic electron microscopy to show that coronaviruses enter human cells through an interaction with angiotensin-converting enzyme 2 (ACE2).
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
Researchers have discovered that a small molecule can help some T cells combat tumours during PD-1 blockade immunotherapy in mice.
Researchers have developed a compound, called AB569, effective at combatting bacteria such as Pseudomonas aeruginosa and have revealed its mechanism of action.
A study has shown that altering amino acid residues in Cas9 to produce new variants can produce a vector with increased gene editing specificity.
Research indicates both S. aureus and S. epidermidis exacerbate skin inflammation, so could be targeted to help treat Netherton syndrome.